{"success":true,"data":{"pressRelease":{"id":"63972","rtpr_id":"nACSH9CWTa","ticker":"ABVX","exchange":"NASDAQ","all_tickers":["ABVX"],"title":"Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Abivax S.A. (ABVX) and Encourages Investors to Learn More About the Investigation","author":"ACCESSWIRE","published_at":"2026-06-15T15:00:02.454Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June\n15, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of Abivax S.A. (\"Abivax\" or \"the Company\")\n(NASDAQ:ABVX). Investors who purchased Abivax securities are encouraged to\nobtain additional information and assist the investigation by visiting the\nfirm's site: bgandg.com/ABVX.\n(https://bgandg.com/ABVX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ABVX)\n(https://app.accessnewswire.com/imagelibrary/87bd6475-6819-404b-ba1e-9ee56779047e/bronstein-gewirtz-and-grossman-llc.png)\nAbivax Investigation Details\n\nOn June 2, 2026, Abivax announced results from its Phase 3 ABTECT clinical\ntrial evaluating obefazimod for the treatment of ulcerative colitis, revealing\nrare cases of malignancy among trial participants. Following this news,\nAbivax's stock price dropped.\n\nWhat's Next for Abivax Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nAbivax securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/ABVX\n(https://bgandg.com/ABVX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ABVX).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Abivax Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Abivax Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1173411)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSH9CWTa","title":"Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Abivax S.A. (ABVX) and Encourages Investors to Learn More About the Investigation","author":"ACCESSWIRE","ticker":"ABVX","created":"2026-06-15T15:00:02.454Z","tickers":["ABVX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / June\n15, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential\nclaims on behalf of purchasers of Abivax S.A. (\"Abivax\" or \"the Company\")\n(NASDAQ:ABVX). Investors who purchased Abivax securities are encouraged to\nobtain additional information and assist the investigation by visiting the\nfirm's site: bgandg.com/ABVX.\n(https://bgandg.com/ABVX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ABVX)\n(https://app.accessnewswire.com/imagelibrary/87bd6475-6819-404b-ba1e-9ee56779047e/bronstein-gewirtz-and-grossman-llc.png)\nAbivax Investigation Details\n\nOn June 2, 2026, Abivax announced results from its Phase 3 ABTECT clinical\ntrial evaluating obefazimod for the treatment of ulcerative colitis, revealing\nrare cases of malignancy among trial participants. Following this news,\nAbivax's stock price dropped.\n\nWhat's Next for Abivax Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nAbivax securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/ABVX\n(https://bgandg.com/ABVX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ABVX).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Abivax Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Abivax Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1173411)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-06-15T15:00:02.520216502Z","server_sent_at_ms":1781535602520},"received_at":"2026-06-15T15:00:02.571Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1173411"},"analysis":{"id":"53393","press_release_id":"63972","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman, LLC announced an investigation into potential securities claims on behalf of Abivax investors.\n\nThe firm cites Abivax's June 2 announcement of rare malignancy cases in its Phase 3 ABTECT trial for obefazimod, which caused a stock price drop.\n\nThis is a routine law-firm solicitation encouraging investors to contact the firm; it is not an issuer disclosure or a court filing.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["obefazimod"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Abivax S.A.","ticker":"ABVX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation announcement."},"tickerRelevance":{"others":[],"primary":"ABVX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman, LLC announced an investigation into potential securities claims on behalf of Abivax investors.\n\nThe firm cites Abivax's June 2 announcement of rare malignancy cases in its Phase 3 ABTECT trial for obefazimod, which caused a stock price drop.\n\nThis is a routine law-firm solicitation encouraging investors to contact the firm; it is not an issuer disclosure or a court filing.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner"},{"name":"Nathan Miller","role":"Client Relations Manager"}],"products":["obefazimod"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Abivax S.A.","ticker":"ABVX"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T15:01:55.662Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":11235,"modelName":"george-droid-qwen-72b"}}